400 related articles for article (PubMed ID: 28497758)
1. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
Petta S; Marzioni M; Russo P; Aghemo A; Alberti A; Ascione A; Antinori A; Bruno R; Bruno S; Chirianni A; Gaeta GB; Giannini EG; Merli M; Messina V; Montilla S; Perno CF; Puoti M; Raimondo G; Rendina M; Silberstein FC; Villa E; Zignego AL; Pani L; Craxì A; ;
Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):427-434. PubMed ID: 28497758
[TBL] [Abstract][Full Text] [Related]
2. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.
Welzel TM; Asselah T; Dumas EO; Zeuzem S; Shaw D; Hazzan R; Forns X; Pilot-Matias T; Lu W; Cohen DE; Feld JJ
Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):494-500. PubMed ID: 28416221
[TBL] [Abstract][Full Text] [Related]
3. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.
Chen CH; Chen CH; Lin CL; Lin CY; Hu TH; Tung SY; Hsieh SY; Lu SN; Chien RN; Hung CH; Sheen IS
Sci Rep; 2019 May; 9(1):7086. PubMed ID: 31068655
[TBL] [Abstract][Full Text] [Related]
4. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
Klibanov OM; Gale SE; Santevecchi B
Ann Pharmacother; 2015 May; 49(5):566-81. PubMed ID: 25680759
[TBL] [Abstract][Full Text] [Related]
5. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
Waked I; Shiha G; Qaqish RB; Esmat G; Yosry A; Hassany M; Soliman R; Mohey MA; Allam N; Zayed N; Asselah T; Hall C; Redman R; Mobashery N; Doss W
Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):36-44. PubMed ID: 28404110
[TBL] [Abstract][Full Text] [Related]
6. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
Asselah T; Hézode C; Qaqish RB; ElKhashab M; Hassanein T; Papatheodoridis G; Feld JJ; Moreno C; Zeuzem S; Ferenci P; Yu Y; Redman R; Pilot-Matias T; Mobashery N
Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):25-35. PubMed ID: 28404108
[TBL] [Abstract][Full Text] [Related]
7. Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.
Khatri A; Mensing S; Podsadecki T; Awni W; Menon R; Dutta S
Clin Drug Investig; 2016 Aug; 36(8):625-35. PubMed ID: 27153823
[TBL] [Abstract][Full Text] [Related]
8. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
Andreone P; Colombo MG; Enejosa JV; Koksal I; Ferenci P; Maieron A; Müllhaupt B; Horsmans Y; Weiland O; Reesink HW; Rodrigues L; Hu YB; Podsadecki T; Bernstein B
Gastroenterology; 2014 Aug; 147(2):359-365.e1. PubMed ID: 24818763
[TBL] [Abstract][Full Text] [Related]
9. Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
Isakov V; Paduta D; Viani RM; Enejosa JV; Pasechnikov V; Znoyko O; Ogurtsov P; Bogomolov PO; Maevskaya MV; Chen X; Shulman NS
Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1073-1076. PubMed ID: 29762255
[TBL] [Abstract][Full Text] [Related]
10. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
Feld JJ; Moreno C; Trinh R; Tam E; Bourgeois S; Horsmans Y; Elkhashab M; Bernstein DE; Younes Z; Reindollar RW; Larsen L; Fu B; Howieson K; Polepally AR; Pangerl A; Shulman NS; Poordad F
J Hepatol; 2016 Feb; 64(2):301-307. PubMed ID: 26476290
[TBL] [Abstract][Full Text] [Related]
11. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
Feld JJ; Kowdley KV; Coakley E; Sigal S; Nelson DR; Crawford D; Weiland O; Aguilar H; Xiong J; Pilot-Matias T; DaSilva-Tillmann B; Larsen L; Podsadecki T; Bernstein B
N Engl J Med; 2014 Apr; 370(17):1594-603. PubMed ID: 24720703
[TBL] [Abstract][Full Text] [Related]
12. Safety assessment in Child A cirrhotic patients treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin.
Manea ED; Stefan I; Olariu C; Calina OC; Jipa RE; Hristea A
Acta Gastroenterol Belg; 2018; 81(1):9-13. PubMed ID: 29562372
[TBL] [Abstract][Full Text] [Related]
13. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
Tronina O; Durlik M; Wawrzynowicz-Syczewska M; Buivydiene A; Katzarov K; Kupcinskas L; Tolmane I; Karpińska E; Pisula A; Karwowska KM; Bolewska B; Jabłkowski M; Rostkowska K; Jakutiene J; Simonova M; Flisiak R
Ann Transplant; 2017 Apr; 22():199-207. PubMed ID: 28386057
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
Ascione A; De Luca M; Melazzini M; Montilla S; Trotta MP; Petta S; Puoti M; Sangiovanni V; Messina V; Bruno S; Izzi A; Villa E; Aghemo A; Zignego AL; Orlandini A; Fontanella L; Gasbarrini A; Marzioni M; Giannini EG; Craxì A;
Infection; 2018 Oct; 46(5):607-615. PubMed ID: 29808463
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
Lawitz E; Makara M; Akarca US; Thuluvath PJ; Preotescu LL; Varunok P; Morillas RM; Hall C; Mobashery N; Redman R; Pilot-Matias T; Vilchez RA; Hézode C
Gastroenterology; 2015 Oct; 149(4):971-80.e1. PubMed ID: 26170136
[TBL] [Abstract][Full Text] [Related]
16. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience.
Yu ML; Chen YL; Huang CF; Lin KH; Yeh ML; Huang CI; Hsieh MH; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL
J Formos Med Assoc; 2018 Jun; 117(6):518-526. PubMed ID: 28662883
[TBL] [Abstract][Full Text] [Related]
17. Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial.
Deutsch L; Houri I; Ben-Ari Z; Shlomai A; Veitsman E; Cohen-Ezra O; Issachar A; Mor O; Gozlan Y; Bruck R; Menachem Y; Zelber-Sagi S; Katchman H; Shibolet O
BMC Infect Dis; 2020 Apr; 20(1):264. PubMed ID: 32245397
[TBL] [Abstract][Full Text] [Related]
18. Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.
Liu CH; Liu CJ; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Kao JH
J Gastroenterol Hepatol; 2018 Mar; 33(3):710-717. PubMed ID: 28762541
[TBL] [Abstract][Full Text] [Related]
19. A Case of Acute Liver Failure during Ritonavir-Boosted Paritaprevir, Ombitasvir and Dasabuvir Therapy in a Patient with HCV Genotype 1b Cirrhosis.
Masetti M; Magalotti D; Martino E; Andreone P; Scuteri A; Zoli M
J Gastrointestin Liver Dis; 2016 Dec; 25(4):559-561. PubMed ID: 27981315
[TBL] [Abstract][Full Text] [Related]
20. Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.
Deeks ED
Drugs; 2015 Jun; 75(9):1027-38. PubMed ID: 26059288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
